Tempus AI (TEM) In-Depth Stock Report
An AI-driven precision medicine company combining genomic testing with a large clinical data library, priced on growth and the path to profitability.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Testing volume grows.
- Data revenue scales.
- Margins improve.
- Pharma contracts expand.
- Tempus AI combines genomic testing with a large clinical data library.
- Testing volume, data deals, and margins drive results.
- Reimbursement and losses are the main concerns.
- Revenue growth, gross margin, and adjusted EBITDA are the key numbers.
- Tempus AI offers genomic testing for cancer patients and licenses de-identified clinical and molecular data.
- Its data library, built from tests and partner health systems, is used by drug developers.
- The company sells software tools that help doctors and researchers use the data.
- It has grown by acquisition, including a genetic testing company.
- The equity debate is whether the data and AI strategy can lift margins and drive sustained growth.
Executive Summary
Tempus combines two revenue engines: genetic testing for patients and data licensing for pharma.
Testing volume creates more data, which in turn makes the data offering more valuable.
Pharma customers pay for access to data and analytics for drug discovery and trials.
The company has reported losses while trying to reach profitability through scale and mix.
The realistic thesis: a data-and-diagnostics platform with real growth, where margins and reimbursement determine value.
Industry & Market Backdrop
The broader competitive and macro environment TEM operates in — context a pure valuation table can't convey on its own.
Precision oncology testing is growing as targeted therapies expand.
Reimbursement from insurers and Medicare shapes testing economics.
Pharma companies spend heavily on data and AI for drug development.
Regulatory oversight of diagnostics and AI is evolving.
Competition includes established genomic testing firms and data companies.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/TEM. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Genomic testing for cancer and other conditions.
Data licensing to pharmaceutical companies.
Software and clinical decision support tools.
Acquired testing and lab capabilities.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
Sells tests to doctors and patients. Volume and reimbursement drive results.
Licenses data and analytics to pharma. It typically has higher margins and lumpier revenue.
Provides tools for clinicians and researchers. It aims to add recurring revenue.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
The company has raised capital through equity and borrowing.
It has been unprofitable but is targeting improved margins.
Acquisitions added scale and debt.
Dilution and leverage are watched.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Founder-led leadership emphasizes data and AI.
Management has set targets for growth and profitability.
Governance is conventional; review the proxy for details.
Demonstrating margin progress is the main test.
See exactly how we get TEM's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our P/E Based | Medium | |
| Our Book Value Based | Medium | |
| ROIC Based | Medium |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this Tempus AI report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Testing volume grows.
- Data revenue scales.
- Margins improve.
- Pharma contracts expand.
- Reimbursement is supportive.
- Losses persist.
- Reimbursement is cut.
- Pharma cuts data spending.
- Competition intensifies.
- Debt weighs.
Related Reports
In-depth reports for other names in Tempus AI's comparable set.
4 catalysts and 4 risks we're tracking for TEM
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this Tempus AI report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- Data deals scale
- Margins improve
- Testing volume grows
- Reimbursement cuts
- Losses persist
- Pharma spending slows
Competitive Positioning
Tempus's edge is a large linked clinical and molecular data set and physician relationships.
Guardant, Exact Sciences, Natera, Illumina, and data firms compete.
Data scale is hard to replicate.
The vulnerability is reimbursement, competition, and losses.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want AI-driven precision medicine exposure with growth.
- Skip it if you dislike unprofitable growth stories.
- Track gross margin and EBITDA.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "TEM fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where TEM is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.